Platinum-Resistant Ovarian CarcinomaPhase 1NCT05225363Papers
Chimeric Antigen Receptor T-cells
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
What the film says
This trial is for platinum-resistant ovarian cancer that has come back, in adults.
The idea: pair a protein degrader with chemotherapy. DT2216 is designed to break down BCL-XL, a protein that helps protect cancer cells from cell death. It is given by vein with weekly paclitaxel. Treatment runs in 28 day cycles, with imaging every two cycles.
This phase 1 study looks for the highest dose that can be given safely, and plans 30 patients. At Dana-Farber Cancer Institute in Boston, Elizabeth Stover leads it.
Public record; not medical advice.
Sources behind this film
Recurrent platinum-resistant ovarian cancer, adults; DT2216 degrades BCL-XL, a protein that protects cancer cells from cell death; Given by vein with weekly paclitaxel; Phase 1; highest safe dose; 30 patients (+2 more lines)
The drug
A proteolysis-targeting chimera (PROTAC) degrader, single-use vial, via intravenous (into the vein) infusion.
An antimicrotubule agent, multi-dose vial, via intravenous (into the vein) infusion per institutional standard.
This phase 1b dose-escalation study is to establish the recommended phase 2 dose and to evaluate the safety of combined dosing of the BCL-XL degrader DT2216 with weekly paclitaxel in recurrent platinum-resistant ovarian cancer. DT2216 is a drug that degrades a protein called BCL-XL which helps to protect cancer cells from cell death. Paclitaxel is an anti-cancer drug that is already used for the treatment of ovarian cancer. The U.S.
The study
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.